http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Edesa Biotech Adds Mechanically Ventilated Patients to Phase 3 ARDS Study
-
Edesa Biotech to Present at H.C. Wainwright Global Investment Conference
-
Edesa Biotech to Present at H.C. Wainwright Global Investment Conference
-
Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results
-
Edesa Biotech (EDSA) Announces Dermatitis Study Enrolling Faster than Expected
-
Edesa Biotech Reports Dermatitis Study Enrolling Faster than Expected
-
Edesa Biotech Appoints Strategy Expert to Board of Directors
-
Edesa Biotech Announces Closing of $10.0 Million Registered Direct Offering
-
Edesa Biotech (EDSA) Announces 2.74M Share Offering at $3.65/sh
-
Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
-
Edesa Biotech (EDSA) Enrolls Over 25% of Subjects for Phase 3 ARDS Study
-
Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study
-
Edesa Biotech Reports Fiscal 1st Quarter 2022 Results
-
Edesa Biotech to Join Ontario Bioscience Panel Discussion
-
Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy
-
Edesa Biotech (EDSA) Reports FY 2021 Results
-
Edesa Biotech Reports Fiscal Year 2021 Results
-
Edesa Biotech Marks Enrollment Milestone in Dermatitis Study
-
Edesa Biotech (EDSA) Expands COVID-19 Clinical Trial to Poland
-
Edesa Biotech Extends COVID-19 Clinical Study to Poland
-
Edesa Biotech to Present at the H.C. Wainwright Global Investment Conference
-
Edesa Biotech Reports Fiscal 3rd Quarter 2021 Financial Results
-
Edesa Biotech Extends Dermatitis Study to Canada
-
Edesa Biotech to Attend BIO Digital 2021
